Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent

Skyclarys From Reata A More Immediate Revenue Source

 
• By Mandy Jackson

CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.

Climb to success - Man working hard and climbing to reach the top of hill
Leqembi and other new products will be slow to add revenue growth • Source: Shutterstock

More from Business

More from Scrip